Madelyn A. Gillentine,Tianyun Wang,Kendra Hoekzema,Jill Rosenfeld,Pengfei Liu,Hui Guo,Chang N. Kim,Bert B. A. De Vries,Lisenka E. L. M. Vissers,Magnus Nordenskjold,Malin Kvarnung,Anna Lindstrand,Ann Nordgren,Jozef Gecz,Maria Iascone,Anna Cereda,Agnese Scatigno,Silvia Maitz,Ginevra Zanni,Enrico Bertini,Christiane Zweier,Sarah Schuhmann,Antje Wiesener,Micah Pepper,Heena Panjwani,Erin Torti,Farida Abid,Irina Anselm,Siddharth Srivastava,Paldeep Atwal,Carlos A. Bacino,Gifty Bhat,Katherine Cobian,Lynne M. Bird,Jennifer Friedman,Meredith S. Wright,Bert Callewaert,Florence Petit,Sophie Mathieu,Alexandra Afenjar,Celenie K. Christensen,Kerry M. White,Orly Elpeleg,Itai Berger,Edward J. Espineli,Christina Fagerberg,Charlotte Brasch-Andersen,Lars Kjærsgaard Hansen,Timothy Feyma,Susan Hughes,Isabelle Thiffault,Bonnie Sullivan,Shuang Yan,Kory Keller,Boris Keren,Cyril Mignot,Frank Kooy,Marije Meuwissen,Alice Basinger,Mary Kukolich,Meredith Philips,Lucia Ortega,Margaret Drummond-Borg,Mathilde Lauridsen,Kristina Sorensen,Anna Lehman,Elena Lopez-Rangel,Paul Levy,Davor Lessel,Timothy Lotze,Suneeta Madan-Khetarpal,Jessica Sebastian,Jodie Vento,Divya Vats,L. Manace Benman,Shane Mckee,Ghayda M. Mirzaa,Candace Muss,John Pappas,Hilde Peeters,Corrado Romano,Maurizio Elia,Ornella Galesi,Marleen E. H. Simon,Koen L. I. van Gassen,Kara Simpson,Robert Stratton,Sabeen Syed,Julien Thevenon,Irene Valenzuela Palafoll,Antonio Vitobello,Marie Bournez,Laurence Faivre,Kun Xia,John Acampado,Rachel K. Earl,Tomasz Nowakowski,Raphael A. Bernier,Evan E. Eichler

Abstract:Background With the increasing number of genomic sequencing studies, hundreds of genes have been implicated in neurodevelopmental disorders (NDDs). The rate of gene discovery far outpaces our understanding of genotype–phenotype correlations, with clinical characterization remaining a bottleneck for understanding NDDs. Most disease-associated Mendelian genes are members of gene families, and we hypothesize that those with related molecular function share clinical presentations. Methods We tested our hypothesis by considering gene families that have multiple members with an enrichment of de novo variants among NDDs, as determined by previous meta-analyses. One of these gene families is the heterogeneous nuclear ribonucleoproteins (hnRNPs), which has 33 members, five of which have been recently identified as NDD genes ( HNRNPK , HNRNPU , HNRNPH1 , HNRNPH2 , and HNRNPR ) and two of which have significant enrichment in our previous meta-analysis of probands with NDDs ( HNRNPU and SYNCRIP ). Utilizing protein homology, mutation analyses, gene expression analyses, and phenotypic characterization, we provide evidence for variation in 12 HNRNP genes as candidates for NDDs. Seven are potentially novel while the remaining genes in the family likely do not significantly contribute to NDD risk. Results We report 119 new NDD cases (64 de novo variants) through sequencing and international collaborations and combined with published clinical case reports. We consider 235 cases with gene-disruptive single-nucleotide variants or indels and 15 cases with small copy number variants. Three hnRNP-encoding genes reach nominal or exome-wide significance for de novo variant enrichment, while nine are candidates for pathogenic mutations. Comparison of HNRNP gene expression shows a pattern consistent with a role in cerebral cortical development with enriched expression among radial glial progenitors. Clinical assessment of probands ( n = 188–221) expands the phenotypes associated with HNRNP rare variants, and phenotypes associated with variation in the HNRNP genes distinguishes them as a subgroup of NDDs. Conclusions Overall, our novel approach of exploiting gene families in NDDs identifies new HNRNP -related disorders, expands the phenotypes of known HNRNP -related disorders, strongly implicates disruption of the hnRNPs as a whole in NDDs, and supports that NDD subtypes likely have shared molecular pathogenesis. To date, this is the first study to identify novel genetic disorders based on the presence of disorders in related genes. We also perform the first phenotypic analyses focusing on related genes. Finally, we show that radial glial expression of these genes is likely critical during neurodevelopment. This is important for diagnostics, as well as developing strategies to best study these genes for the development of therapeutics.

Penetrance, variable expressivity and monogenic neurodevelopmental disorders

Genetic modifiers and ascertainment drive variable expressivity of complex disorders

Understanding neurodevelopmental proteasomopathies as new rare disease entities: A review of current concepts, molecular biomarkers, and perspectives

A systematic review and pooled analysis of penetrance estimates of copy number variants associated with neurodevelopment

Investigating the role of common cis-regulatory variants in modifying penetrance of putatively damaging, inherited variants in severe neurodevelopmental disorders

Common genetic variants contribute to risk of rare severe neurodevelopmental disorders

Mono and biallelic variants in cause severe neurodevelopmental disorders

Genomic and phenotypic characterization of 404 individuals with neurodevelopmental disorders caused by CTNNB1 variants

MYT1L-associated neurodevelopmental disorder: description of 40 new cases and literature review of clinical and molecular aspects

Clinical and genetic characterization of patients segregating variants in KPTN, MINPP1, NGLY1, AP4B1, and SON underlying neurodevelopmental disorders: Genetic and phenotypic expansion

Assessment of parental mosaicism rates in neurodevelopmental disorders caused by apparent de novo pathogenic variants using deep sequencing

The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder

Regulatory De Novo Mutations Underlying Intellectual Disability

Multiple molecular diagnoses in the field of intellectual disability and congenital anomalies: 3.5% of all positive cases

Dissecting the contribution of common variants to risk of rare neurodevelopmental conditions

Rare deleterious mutations of HNRNP genes result in shared neurodevelopmental disorders

Unveiling the crucial neuronal role of the proteasomal ATPase subunit gene in neurodevelopmental proteasomopathies

Using medical exome sequencing to identify the causes of neurodevelopmental disorders: Experience of 2 clinical units and 216 patients

Regulatoryde Novomutations Underlying Intellectual Disability

A study concept of expeditious clinical enrollment for genetic modifier studies in Charcot–Marie–Tooth neuropathy 1A

Assessment of Rare Genetic Variants to Identify Candidate Modifier Genes Underlying Neurological Manifestations in Neurofibromatosis 1 Patients